Kyntra BioLTS:0IL8 -1.94%50 Market Cap is $30.16 Mil as of Jul. 09, 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,421 Biotechnology companies, Kyntra Bio ranks worse than 71.08% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kyntra Bio's share price for the quarter that ended in Mar. 2026 was $6.69. Kyntra Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 4.05 Mil. Therefore, Kyntra Bio's market cap for the quarter that ended in Mar. 2026 was $27.08 Mil.
Kyntra Bio's quarterly market cap
declined
from Sep. 2025 ($49.33 Mil) to Dec. 2025 ($35.05 Mil) and
declined
from Dec. 2025 ($35.05 Mil) to Mar. 2026 ($27.08 Mil).
Kyntra Bio's annual market cap
declined
from Dec. 2023 ($85.35 Mil) to Dec. 2024 ($50.70 Mil) and
declined
from Dec. 2024 ($50.70 Mil) to Dec. 2025 ($35.05 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kyntra Bio's Enterprise Value for Today is $115.03 Mil.
Kyntra Bio (LTS:0IL8) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Kyntra Bio Market Cap Related Terms
Kyntra Bio Market Cap Historical Data
* Premium members only.
The historical data trend for Kyntra Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0IL8 vs TVGN, PSTV, GRDX: Market Cap Comparison
For the Biotechnology subindustry, Kyntra Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyntra Bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kyntra Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Kyntra Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Kyntra Bio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyntra Bio (LTS:0IL8) has a Market Cap of $30.16 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kyntra Bio and its competitors. According to the industry distribution chart, Kyntra Bio ranks #1010 out of 1421 companies in the Biotechnology industry, placing it in the top 71.1%.
Is Kyntra Bio's Market Cap too high?
Kyntra Bio's current Market Cap is $30.16 Mil. The Biotechnology industry median Market Cap is 119.86. Kyntra Bio's value of $30.16 Mil is 74.8% below this industry median. Based on the distribution chart, Kyntra Bio ranks #1010 out of 1421 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Market Cap compare to TVGN and PSTV?
According to the Biotechnology industry distribution chart, Kyntra Bio ranks #1010 out of 1421 companies for Market Cap. This places Kyntra Bio in the lower half of its industry. The industry median Market Cap is 119.86. Kyntra Bio's value of $30.16 Mil is 74.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.86, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyntra Bio's current Market Cap of $30.16 Mil is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Kyntra Bio and its competitors. For the Biotechnology industry, the median Market Cap is 119.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyntra Bio's current Market Cap is $30.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current Market Cap is $30.16 Mil and 74.8% below the Biotechnology industry median of 119.86. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Market Cap is $30.16 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?
Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued.
The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70.
GuruFocus considers Kyntra Bio to be Significantly Overvalued.
Key valuation signals for LTS:0IL8:
Market Cap: $30.16 Mil
GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
Industry Position: 74.8% below the Biotechnology median (#1010 of 1421)
No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score
Get the complete analysis for LTS:0IL8
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0IL8 has been successfully added to your 
